Market Scenario , Drug discovery is the process of designing a new drug. The most common methods employed for drug discovery are molecular manipulation, random screening, drug metabolites, molecular designing, and serendipity. Drug discovery services are specifically designed to minimize the costs and timelines of drug discovery., It is noted that the increasing demand for cancer treatment, technological advancements, and increasing healthcare expenditure are the key factors driving the drug discovery services market. According to the World Health Organization (WHO), cancer is one of the leading causes of mortality worldwide. The disease was responsible for 8.8 million deaths in 2015. The most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer. Cancer-causing infections are responsible for up to 25% cases of cancer in the low- and middle-income countries., Various other factors such as the growing awareness about chronic diseases, increasing patient pool, unmet medical needs, patent expiration of blockbuster drugs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global drug discovery services market. , Despite these drivers, there are some setbacks associated with the drug discovery services market. The huge capital investment with low-profit margins, strict FDA regulations, and poor healthcare system in low and middle-income countries may hinder the growth of the drug discovery services market to a considerable extent. , It is estimated that the drug discovery services market is expected to grow at a CAGR of 10.8% during the forecast period of 2017–2023., , Key Players, Some of the key players in the global drug discovery services market are Abbott Laboratories Inc., Advinus Therapeutics, Agilent Technologies Ubiquigent, Albany Molecular Research Inc. (AMRI), AstraZeneca PLC, Aurigene, Bayer AG, Charles River Laboratories International, ChemBridge Corporation, Covance, Eli Lilly and Company, Evotec, Domainex, F. Hoffmann-La Roche Ltd, GE Healthcare, GenScript, GlaxoSmithKline LLC, GVK Biosciences, Jubilant Biosys, Lonza, Merck, Pharmaceutical Product De

Market Scenario

Drug discovery is the process of designing a new drug. The most common methods employed for drug discovery are molecular manipulation, random screening, drug metabolites, molecular designing, and serendipity. Drug discovery services are specifically designed to minimize the costs and timelines of drug discovery.

It is noted that the increasing demand for cancer treatment, technological advancements, and increasing healthcare expenditure are the key factors driving the drug discovery services market. According to the World Health Organization (WHO), cancer is one of the leading causes of mortality worldwide. The disease was responsible for 8.8 million deaths in 2015. The most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer. Cancer-causing infections are responsible for up to 25% cases of cancer in the low- and middle-income countries.

Various other factors such as the growing awareness about chronic diseases, increasing patient pool, unmet medical needs, patent expiration of blockbuster drugs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global drug discovery services market.

Despite these drivers, there are some setbacks associated with the drug discovery services market. The huge capital investment with low-profit margins, strict FDA regulations, and poor healthcare system in low and middle-income countries may hinder the growth of the drug discovery services market to a considerable extent.

It is estimated that the drug discovery services market is expected to grow at a CAGR of 10.8% during the forecast period of 2017–2023.



Key Players

Some of the key players in the global drug discovery services market are Abbott Laboratories Inc., Advinus Therapeutics, Agilent Technologies Ubiquigent, Albany Molecular Research Inc. (AMRI), AstraZeneca PLC, Aurigene, Bayer AG, Charles River Laboratories International, ChemBridge Corporation, Covance, Eli Lilly and Company, Evotec, Domainex, F. Hoffmann-La Roche Ltd, GE Healthcare, GenScript, GlaxoSmithKline LLC, GVK Biosciences, Jubilant Biosys, Lonza, Merck, Pharmaceutical Product Development, LLC (PPD), Piramal Enterprises, Promega Corporation, Selcia Limited, Shimadzu Corp., SRI International, Syngene International Ltd., Thermo Fisher Scientific, Viva Biotech, WuXi AppTec, and others.

Intended Audience



Pharmaceutical Companies



Research and Development (R&D) Companies



Diagnostic Laboratories



Government Research Institutes



Academic Institutes and Universities



Segmentation

The global drug discovery services market is segmented by drug type, types of services, technology, therapeutic area, process, and end-user.

On the basis of drug type, the drug discovery services market is classified as small molecule drug and biologics drug.

On the basis of types of services, the drug discovery services market is classified as Drug Metabolism and Pharmacokinetics (DMPK) services, pharmaceutical services, medicinal chemistry, and biological services.

On the basis of technology, the drug discovery services market is classified as high throughput screening, biochips, pharmacogenomics and pharmacogenetics, combinatorial chemistry, nanotechnology, spectroscopy, metabolomics, and others.

On the basis of therapeutic area, the drug discovery services market is classified as oncology, neurology, cardiovascular diseases, respiratory diseases, diabetes, and others.

On the basis of process, the drug discovery services market is classified as target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation.

On the basis of end-user, the drug discovery services market is segmented into hospitals and clinics, pharmaceutical companies, biotechnology companies, research institutes, and others.

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Regional Analysis

The Americas dominates the drug discovery services market owing to the increasing prevalence of chronic diseases and high healthcare expenditure. According to the data suggested by the Center for Disease Control and Prevention (CDC), around 92.1 million adults have at least one type of cardiovascular disease. It is also reported that around 15.1% of adults in the United States i.e. 36.5 million adults smoked cigarettes in 2015, which accounted for more than 480,000 deaths each year. Nearly 86% of the healthcare cost in the United States i.e. USD 2.7 trillion is spent for people with chronic and mental health conditions.

Europe holds the second position in the drug discovery services market. The financial support by the government towards research and development and patent expiration of various blockbuster drugs are expected to drive the European drug discovery services market. Various biologic drugs such as Genentech's Rituxan, Abbott & Eisai's Humira, and J&J's Remicade are likely to lose their patent protection in the coming years.

Asia Pacific is the fastest growing drug discovery services market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.

The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.



Global Drug Discovery Services Market, by Region



Americas





North America







US







Canada







Latin America





Europe





Western Europe







Germany







France







Italy







Spain







UK







Rest of Western Europe







Eastern Europe





Asia-Pacific





Japan





China





India





Australia





South Korea





Rest of Asia-Pacific





The Middle East & Africa





Middle East





Africa





Frequently Asked Questions (FAQ) :